Nateglinide is an oral antihyperglycemic agent. It belongs to the meglitinide class of short-acting insulin secretagogues.
Global Nateglinide Market: Introduction
Nateglinide is an oral antihyperglycemic agent. It belongs to the meglitinide class of short-acting insulin secretagogues. It is used for the treatment of non-insulin-dependent diabetes mellitus. The agent acts by binding to β cells of the pancreas to stimulate and regulate insulin release. Nateglinide is an amino acid derivative. It induces an early insulin response to meals decreasing postprandial blood glucose levels. Meglitinides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Meglitinides may cause hypoglycemia due to their mechanism of action. However, the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. Nateglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program.
Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). Major metabolites possess less activity than the parent compound.
Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76651
Key Drivers of Global Nateglinide Market
Rapid Growth in Prevalence of Diabetes
According to the World Health Organization (WHO), the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. The global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Diabetes prevalence has been rising more rapidly in middle- and low-income countries. Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke, and lower limb amputation. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Another 2.2 million deaths were attributable to high blood glucose in 2012. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. The WHO estimated that diabetes was the seventh leading cause of death in 2016.
Increase in Prevalence of Obesity
According to the WHO, global prevalence of obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these, over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population lives in countries where overweight and obesity kills more people than underweight. 40 million children under the age of 5 were overweight or obese in 2018. Over 340 million children and adolescents aged 5 to 19 were overweight or obese in 2016.
Request for Analysis of COVID19 Impact on Nateglinide Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76651
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Pre-book Nateglinide Market Report –https://www.transparencymarketresearch.com/checkout.php?rep_id=76651<ype=S
Key Players Operating in Global Nateglinide Market
The global nateglinide market is highly consolidated, with the presence of a small number of key players. Leading players operating in the global nateglinide market are:
- Novartis Europharm Limited
- Caremark L.L.C.
- AvKARE, Inc.
- Avera McKennan Hospital
- Zydus Pharmaceuticals (USA) Inc.
- Nivagen Pharmaceuticals, Inc.
- American Health Packaging
- Par Pharmaceutical, Inc.
- Wilshire Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Limited
- Cadila Healthcare Limited
- Actavis Pharma, Inc.
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Mr. Rohit Bhisey
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453